Globe Catheter and Globe Pulsed Field System
Kardium, Inc. · Decision date Oct 27, 2026
What did the FDA approve?
FDA lists PMA supplement P240044/S007 for Kardium, Inc.'s Globe® Catheter and Globe® Pulsed Field System as approved on 2026-10-27. The supplement is classified as a Real-Time Process change for design/components/specifications/material. The S007 suffix ties the record to the original P240044 approval rather than constituting a separate approval of the complete system.
The reported purpose is an update to the flexible circuits of the Globe® Catheter array, which uses irreversible electroporation for atrial fibrillation ablation in the cardiovascular category under product code QZI. Beyond this field-level description, the database entry does not disclose the prior circuit design, the nature of the change, test methods, or performance results, and it does not present independent proof of safety or clinical effectiveness; the approval status is the agency's decision on the manufacturing change as described.
FDA approval order statement
approval for update to the flexible circuits of the Globe Catheter array
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 27, 2026
- FDA change category
- Change Design/Components/Specifications/Material
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P240044/S007
- Regulatory pathway
- PMA supplement
- Applicant
- Kardium, Inc.
- Product code
- QZI
- Decision code
- APPR
- Decision date
- Oct 27, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation.
- Applicant
- Kardium, Inc.
- Product code
- QZI
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P240044. Subsequent supplements may change the device or its indications.
FDA decision timeline
P240044 · Original PMA
Globe Pulsed Field System
P240044/S007 received
Application receipt date recorded by FDA.
P240044/S008 · Related supplement
Globe Pulsed Field System; Globe Catheter
P240044/S007 · FDA decision
Real-Time Process
Timeline entries are records held by MedtechLedger for P240044. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240044
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Globe Pulsed Field SystemP240044 | Kardium, Inc. | PMA approval | Aug 27, 2025 | FDA |
Globe Pulsed Field System; Globe CatheterP240044/S008 | Kardium, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Explore the linked device profile
Other records with product code QZI
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Varipulse Bi-Directional CatheterP240006/S018 | Biosense Webster, Inc. | PMA supplement | Nov 3, 2026 | FDA |
Volt PFA SystemP250022/S002 | ABBOTT MEDICAL | PMA supplement | Oct 15, 2026 | FDA |
Affera Sphere-9 Mapping and Ablation CatheterP240013/S032 | Medtronic, Inc. | PMA supplement | Oct 9, 2026 | FDA |
Volt PFA Catheter, Sensor EnabledP250022/S009 | ABBOTT MEDICAL | PMA supplement | Oct 8, 2026 | FDA |
VOLT PFA CATHETER, SENSOR ENABLEDP250022/S012 | ABBOTT MEDICAL | PMA supplement | Oct 8, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Kardium, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 8518 Glenlyon Pkwy., Unit 155, Burnaby, V5J OB6
Sources and methodology
- Original FDA record: P240044/S007
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

